Legis Daily

Infectious Disease Therapies Research and Innovation Act of 2020

USA116th CongressHR-7537| House 
| Updated: 7/9/2020
Mike Kelly

Mike Kelly

Republican Representative

Pennsylvania

Ways and Means Committee, Health Subcommittee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Infectious Disease Therapies Research and Innovation Act of 2020 This bill exempts from the definition of passive activity , for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity. The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jul 9, 2020
Introduced in House
Jul 9, 2020
Referred to the House Committee on Ways and Means.
Jul 9, 2020
Referred to the Subcommittee on Health.
  • July 9, 2020
    Introduced in House


  • July 9, 2020
    Referred to the House Committee on Ways and Means.


  • July 9, 2020
    Referred to the Subcommittee on Health.

Taxation

Related Bills

  • HR 116-14: Commitment to Defeat the Virus and Keep America Healthy Act
Accounting and auditingAdvanced technology and technological innovationsBusiness investment and capitalIncome tax creditsInfectious and parasitic diseasesMedical researchSmall businessTax administration and collection, taxpayers

Infectious Disease Therapies Research and Innovation Act of 2020

USA116th CongressHR-7537| House 
| Updated: 7/9/2020
Infectious Disease Therapies Research and Innovation Act of 2020 This bill exempts from the definition of passive activity , for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity. The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jul 9, 2020
Introduced in House
Jul 9, 2020
Referred to the House Committee on Ways and Means.
Jul 9, 2020
Referred to the Subcommittee on Health.
  • July 9, 2020
    Introduced in House


  • July 9, 2020
    Referred to the House Committee on Ways and Means.


  • July 9, 2020
    Referred to the Subcommittee on Health.
Mike Kelly

Mike Kelly

Republican Representative

Pennsylvania

Ways and Means Committee, Health Subcommittee

Taxation

Related Bills

  • HR 116-14: Commitment to Defeat the Virus and Keep America Healthy Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Accounting and auditingAdvanced technology and technological innovationsBusiness investment and capitalIncome tax creditsInfectious and parasitic diseasesMedical researchSmall businessTax administration and collection, taxpayers